News >

Atezolizumab/Bevacizumab Combo Improves Survival in Frontline HCC

Gina Columbus
Published: Monday, Oct 21, 2019

Levi Garraway, MD, PhD

Levi Garraway, MD, PhD
The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) showed statistically significant and clinically meaningful improvements in both progression-free and overall survival (OS) compared with sorafenib (Nexavar) in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior therapy, meeting the coprimary endpoints of the IMbrave150 trial (NCT03434379).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication